A new horizon in the phosphorylated sites of AGA: the structural impact of C163S mutation in aspartylglucosaminuria through molecular dynamics simulation

References

• Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1–2, 19–25. https://doi.org/10.1016/j.softx.2015.06.001
   Google Scholar
• Akhunzada, M. J., Yoon, H. J., Deb, I., Braka, A., & Wu, S. (2022). Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands targeting G-protein-coupled receptors. Scientific Reports, 12(1), 15972. https://doi.org/10.1038/s41598-022-20065-2
   PubMed Web of Science ®Google Scholar
• Ali, S., Khan, F. I., Mohammad, T., Lan, D., Hassan, Md. I., & Wang, Y. (2019). Identification and Evaluation of Inhibitors of Lipase from Malassezia restricta using Virtual High-Throughput Screening and Molecular Dynamics Studies. International Journal of Molecular Sciences, 20(4), 884. https://doi.org/10.3390/ijms20040884
   Google Scholar
• Almeida, V. M., Dias, Ê. R., Souza, B. C., Cruz, J. N., Santos, C. B. R., Leite, F. H. A., Queiroz, R. F., & Branco, A. (2022). Methoxylated flavonols from Vellozia dasypus Seub ethyl acetate active myeloperoxidase extract: In vitro and in silico assays. Journal of Biomolecular Structure & Dynamics, 40(16), 7574–7583. https://doi.org/10.1080/07391102.2021.1900916
   PubMed Web of Science ®Google Scholar
• Apweiler, R., Bairoch, A., Wu, C. H., Barker, W. C., Boeckmann, B., Ferro, S., Gasteiger, E., Huang, H., Lopez, R., Magrane, M., Martin, M. J., Natale, D. A., O'Donovan, C., Redaschi, N., & Yeh, L.-S. L. (2004). UniProt: The Universal Protein knowledgebase. Nucleic Acids Research, 32(Database issue), D115–D119. https://doi.org/10.1093/nar/gkh131
   PubMed Web of Science ®Google Scholar
• Ardalan, N., Mirzaie, S., Sepahi, A. A., & Khavari-Nejad, R. A. (2018). Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies. Medical Hypotheses, 112, 7–17. https://doi.org/10.1016/j.mehy.2018.01.004
   PubMed Web of Science ®Google Scholar
• Arvio, M., & Mononen, I. (2016). Aspartylglycosaminuria: A review. Orphanet Journal of Rare Diseases, 11(1), 162. https://doi.org/10.1186/s13023-016-0544-6
   PubMedGoogle Scholar
• Arvio, M., Sauna-Aho, O., & Peippo, M. (2001). Bone marrow transplantation for aspartylglucosaminuria: Follow-up study of transplanted and non-transplanted patients. The Journal of Pediatrics, 138(2), 288–290. https://doi.org/10.1067/mpd.2001.110119
   PubMed Web of Science ®Google Scholar
• Arvio, P., & Arvio, M. (2002). Progressive nature of aspartylglucosaminuria. Acta Paediatrica (Oslo, Norway : 1992), 91(3), 255–257. https://doi.org/10.1080/08035250252833842
   PubMed Web of Science ®Google Scholar
• Arvio, P., Arvio, M., & Pirinen, S. (1997). Characteristic dental arches and occlusion in patients with aspartylglucosaminuria. Journal of Craniofacial Genetics and Developmental Biology, 17(3), 133–140.
   PubMedGoogle Scholar
• Arvio, P., Arvio, M., Kero, M., Pirinen, S., & Lukinmaa, P. L. (1999). Overgrowth of oral mucosa and facial skin, a novel feature of aspartylglucosaminuria. Journal of Medical Genetics, 36(5), 398–404.
   PubMed Web of Science ®Google Scholar
• Banning, A., Gülec, C., Rouvinen, J., Gray, S. J., & Tikkanen, R. (2016). Identification of small molecule compounds for pharmacological chaperone therapy of aspartylglucosaminuria. Scientific Reports, 6(1), 37583. https://doi.org/10.1038/srep37583
   PubMedGoogle Scholar
• Brooks, B. R., Brooks, C. L., Mackerell, A. D., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., Caflisch, A., Caves, L., Cui, Q., Dinner, A. R., Feig, M., Fischer, S., Gao, J., Hodoscek, M., Im, W., … Karplus, M. (2009). CHARMM: The biomolecular simulation program. Journal of Computational Chemistry, 30(10), 1545–1614. https://doi.org/10.1002/jcc.21287
   PubMed Web of Science ®Google Scholar
• Chen, X., Snanoudj-Verber, S., Pollard, L., Hu, Y., Cathey, S. S., Tikkanen, R., & Gray, S. J. (2021). Pre-clinical gene therapy with AAV9/AGA in aspartylglucosaminuria mice provides evidence for clinical translation. Molecular Therapy, 29(3), 989–1000. https://doi.org/10.1016/j.ymthe.2020.11.012
   PubMed Web of Science ®Google Scholar
• Condic-Jurkic, K., Subramanian, N., Mark, A. E., & O'Mara, M. L. (2018). The reliability of molecular dynamics simulations of the multidrug transporter P-glycoprotein in a membrane environment. PLoS One, 13(1), e0191882. https://doi.org/10.1371/journal.pone.0191882
   PubMed Web of Science ®Google Scholar
• de Almeida, R. B. M., Barbosa, D. B., do Bomfim, M. R., Amparo, J. A. O., Andrade, B. S., Costa, S. L., Campos, J. M., Cruz, J. N., Santos, C. B. R., Leite, F. H. A., & Botura, M. B. (2023). Identification of a novel dual inhibitor of acetylcholinesterase and butyrylcholinesterase: In vitro and in silico studies. Pharmaceuticals, 16(1), 95. https://doi.org/10.3390/ph16010095
   Web of Science ®Google Scholar
• Dunder, U., Kaartinen, V., Valtonen, P., Väänänen, E., Kosma, V. M., Heisterkamp, N., Groffen, J., & Mononen, I. (2000). Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 14(2), 361–367. https://doi.org/10.1096/fasebj.14.2.361
   PubMed Web of Science ®Google Scholar
• Dunder, U., Valtonen, P., Kelo, E., & Mononen, I. (2010). Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice. Journal of Inherited Metabolic Disease, 33(5), 611–617. https://doi.org/10.1007/s10545-010-9158-7
   PubMed Web of Science ®Google Scholar
• Enomaa, N., Danos, O., Peltonen, L., & Jalanko, A. (1995). Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer. Human Gene Therapy, 6(6), 723–731. https://doi.org/10.1089/hum.1995.6.6-723
   PubMed Web of Science ®Google Scholar
• Filipe, H. A. L., & Loura, L. M. S. (2022). Molecular dynamics simulations: Advances and applications. Molecules, 27(7), 2105. https://doi.org/10.3390/molecules27072105
   PubMed Web of Science ®Google Scholar
• Fisher, K. J., & Aronson, N. N. (1991). Characterization of the mutation responsible for aspartylglucosaminuria in three Finnish patients. Amino acid substitution Cys163—Ser abolishes the activity of lysosomal glycosylasparaginase and its conversion into subunits. The Journal of Biological Chemistry, 266(18), 12105–12113. https://doi.org/10.1016/S0021-9258(18)99071-X
   PubMed Web of Science ®Google Scholar
• Hoover, N. (1985). Canonical dynamics: Equilibrium phase-space distributions. Physical Review. A, General Physics, 31(3), 1695–1697. https://doi.org/10.1103/physreva.31.1695
   PubMedGoogle Scholar
• Hornbeck, P. V., Kornhauser, J. M., Latham, V., Murray, B., Nandhikonda, V., Nord, A., Skrzypek, E., Wheeler, T., Zhang, B., & Gnad, F. (2019). 15 years of PhosphoSitePlus®: Integrating post-translationally modified sites, disease variants and isoforms. Nucleic Acids Research, 47(D1), D433–D441. https://doi.org/10.1093/nar/gky1159
   PubMed Web of Science ®Google Scholar
• Hornbeck, P. V., Kornhauser, J. M., Tkachev, S., Zhang, B., Skrzypek, E., Murray, B., Latham, V., & Sullivan, M. (2012). PhosphoSitePlus: A comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Research, 40(Database issue), D261–D270. https://doi.org/10.1093/nar/gkr1122
   PubMedGoogle Scholar
• Ikonen, E., Baumann, M., Grön, K., Syvänen, A. C., Enomaa, N., Halila, R., Aula, P., & Peltonen, L. (1991). Aspartylglucosaminuria: CDNA encoding human aspartylglucosaminidase and the missense mutation causing the disease. The EMBO Journal, 10(1), 51–58. https://doi.org/10.1002/j.1460-2075.1991.tb07920.x
   PubMed Web of Science ®Google Scholar
• Ikonen, E., Enomaa, N., Ulmanen, I., & Peltonen, L. (1991). In vitro mutagenesis helps to unravel the biological consequences of aspartylglucosaminuria mutation. Genomics, 11(1), 206–211. https://doi.org/10.1016/0888-7543(91)90120-4
   PubMed Web of Science ®Google Scholar
• Ikonen, E., Syvänen, A. C., & Peltonen, L. (1993). Dissection of the molecular pathology of aspartylglucosaminuria provides the basis for DNA diagnostics and future therapeutic interventions. Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum, 213, 19–27. https://doi.org/10.3109/00365519309090670
   PubMedGoogle Scholar
• Jo, S., Cheng, X., Islam, S. M., Huang, L., Rui, H., Zhu, A., Lee, H. S., Qi, Y., Han, W., Vanommeslaeghe, K., MacKerell, A. D., Roux, B., & Im, W. (2014). CHARMM-GUI PDB manipulator for advanced modeling and simulations of proteins containing nonstandard residues. Advances in Protein Chemistry and Structural Biology, 96, 235–265. https://doi.org/10.1016/bs.apcsb.2014.06.002
   PubMed Web of Science ®Google Scholar
• Jo, S., Kim, T., Iyer, V. G., & Im, W. (2008). CHARMM-GUI: A web-based graphical user interface for CHARMM. Journal of Computational Chemistry, 29(11), 1859–1865. https://doi.org/10.1002/jcc.20945
   PubMed Web of Science ®Google Scholar
• Kato, K., Nakayoshi, T., Fukuyoshi, S., Kurimoto, E., & Oda, A. (2017). Validation of molecular dynamics simulations for prediction of three-dimensional structures of small proteins. Molecules, 22(10), 1716. https://doi.org/10.3390/molecules22101716
   PubMed Web of Science ®Google Scholar
• Kyttälä, A., Heinonen, O., Peltonen, L., & Jalanko, A. (1998). Expression and endocytosis of lysosomal aspartylglucosaminidase in mouse primary neurons. The Journal of Neuroscience, 18(19), 7750–7756. https://doi.org/10.1523/JNEUROSCI.18-19-07750.1998
   PubMed Web of Science ®Google Scholar
• Laskowski, R. A., Rullmannn, J. A., MacArthur, M. W., Kaptein, R., & Thornton, J. M. (1996). AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR. Journal of Biomolecular NMR, 8(4), 477–486. https://doi.org/10.1007/BF00228148
   PubMed Web of Science ®Google Scholar
• Lee, J., Cheng, X., Swails, J. M., Yeom, M. S., Eastman, P. K., Lemkul, J. A., Wei, S., Buckner, J., Jeong, J. C., Qi, Y., Jo, S., Pande, V. S., Case, D. A., Brooks, C. L., MacKerell, A. D., Klauda, J. B., & Im, W. (2016). CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field. Journal of Chemical Theory and Computation, 12(1), 405–413. https://doi.org/10.1021/acs.jctc.5b00935
   PubMed Web of Science ®Google Scholar
• Li, W., Ma, J., Wu, S., Zhang, J., & Cheng, J. (2021). The effect of hydrogen bond on the thermal and mechanical properties of furan epoxy resins: Molecular dynamics simulation study. Polymer Testing, 101, 107275. https://doi.org/10.1016/j.polymertesting.2021.107275
   Web of Science ®Google Scholar
• Lima, A. d M., Siqueira, A. S., Möller, M. L. S., Souza, R. C. d., Cruz, J. N., Lima, A. R. J., Silva, R. C. d., Aguiar, D. C. F., Junior, J. L. d S. G. V., & Gonçalves, E. C. (2022). In silico improvement of the cyanobacterial lectin microvirin and mannose interaction. Journal of Biomolecular Structure & Dynamics, 40(3), 1064–1073. https://doi.org/10.1080/07391102.2020.1821782
   PubMed Web of Science ®Google Scholar
• Liu, Y., Dunn, G. S., & Aronson, N. N. (1996). Purification, biochemistry and molecular cloning of an insect glycosylasparaginase from Spodoptera frugiperda. Glycobiology, 6(5), 527–536. https://doi.org/10.1093/glycob/6.5.527
   PubMed Web of Science ®Google Scholar
• McCormack, A. L., Mononen, I., Kaartinen, V., & Yates, J. R. (1995). Localization of the disulfide bond involved in post-translational processing of glycosylasparaginase and disrupted by a mutation in the Finnish-type aspartylglycosaminuria. The Journal of Biological Chemistry, 270(7), 3212–3215. https://doi.org/10.1074/jbc.270.7.3212
   PubMed Web of Science ®Google Scholar
• Mononen, I., Fisher, K. J., Kaartinen, V., & Aronson, N. N. (1993). Aspartylglycosaminuria: Protein chemistry and molecular biology of the most common lysosomal storage disorder of glycoprotein degradation. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 7(13). https://doi.org/10.1096/fasebj.7.13.8405810
   PubMed Web of Science ®Google Scholar
• Mukherjee, S., & Bahadur, R. P. (2018). An account of solvent accessibility in protein-RNA recognition. Scientific Reports, 8(1). https://doi.org/10.1038/s41598-018-28373-2
   Google Scholar
• Noronkoski, T., Stoineva, I. B., Petkov, D. D., & Mononen, I. (1997). Recombinant human glycosylasparaginase catalyzes hydrolysis of L-asparagine. FEBS Letters, 412(1), 149–152. https://doi.org/10.1016/s0014-5793(97)00761-8
   PubMed Web of Science ®Google Scholar
• Oinonen, C., Tikkanen, R., Rouvinen, J., & Peltonen, L. (1995). Three-dimensional structure of human lysosomal aspartylglucosaminidase. Nature Structural Biology, 2(12), 1102–1108. https://doi.org/10.1038/nsb1295-1102
   PubMedGoogle Scholar
• Parra-Cruz, R., Jäger, C. M., Lau, P. L., Gomes, R. L., & Pordea, A. (2018). Rational design of thermostable carbonic anhydrase mutants using molecular dynamics simulations. The Journal of Physical Chemistry B, 122(36), 8526–8536. https://doi.org/10.1021/acs.jpcb.8b05926
   PubMed Web of Science ®Google Scholar
• Peltola, M., Tikkanen, R., Peltonen, L., & Jalanko, A. (1996). Ser72Pro active-site disease mutation in human lysosomal aspartylglucosaminidase: Abnormal intracellular processing and evidence for extracellular activation. Human Molecular Genetics, 5(6), 737–743. https://doi.org/10.1093/hmg/5.6.737
   PubMed Web of Science ®Google Scholar
• Riikonen, A., Rouvinen, J., Tikkanen, R., Julkunen, I., Peltonen, L., & Jalanko, A. (1996). Primary folding of aspartylglucosaminidase. Significance of disulfide bridges and evidence of early multimerization. The Journal of Biological Chemistry, 271(35), 21340–21344. https://doi.org/10.1074/jbc.271.35.21340
   PubMed Web of Science ®Google Scholar
• Saarela, J., Laine, M., Oinonen, C., Jalanko, A., Rouvinen, J., Peltonen, L., & Tikkanen, R. (1998). Activation and oligomerization of aspartylglucosaminidase. The Journal of Biological Chemistry, 273(39), 25320–25328. https://doi.org/10.1074/jbc.273.39.25320
   PubMed Web of Science ®Google Scholar
• Saito, S., Ohno, K., Sugawara, K., Suzuki, T., Togawa, T., & Sakuraba, H. (2008). Structural basis of aspartylglucosaminuria. Biochemical and Biophysical Research Communications, 377(4), 1168–1172. https://doi.org/10.1016/j.bbrc.2008.10.142
   PubMed Web of Science ®Google Scholar
• Silva, L. B., Ferreira, E. F. B., Maryam, Espejo-Román, J. M., Costa, G. V., Cruz, J. V., Kimani, N. M., Costa, J. S., Bittencourt, J. A. H. M., Cruz, J. N., Campos, J. M., & C. B. R., Santos. (2023). Galantamine based novel acetylcholinesterase enzyme inhibitors: A molecular modeling design approach. Molecules, 28(3), 1035. https://doi.org/10.3390/molecules28031035
   PubMed Web of Science ®Google Scholar
• Sriroopreddy, R., Raghuraman, P., Sreeshma, J., Kamalesh, D., & Sudandiradoss, C. (2021). Exploring the structural significance of molecular switch mechanism alias motif phosphorylation in Wnt/β-catenin and their crucial role in triple-negative breast cancer. Archives of Biochemistry and Biophysics, 698, 108722. https://doi.org/10.1016/j.abb.2020.108722
   PubMed Web of Science ®Google Scholar
• Sui, L., Lakshminarasimhan, D., Pande, S., & Guo, H.-C. (2014). Structural basis of a point mutation that causes the genetic disease aspartylglucosaminuria. Structure (London, England : 1993), 22(12), 1855–1861. https://doi.org/10.1016/j.str.2014.09.014
   PubMed Web of Science ®Google Scholar
• Tanaka, M., Kono, M., & Yamashina, I. (1973). Specificity studies of 4-L-aspartylglycosylamine amido hydrolase. Journal of Biochemistry, 73(6), 1285–1289. https://doi.org/10.1093/oxfordjournals.jbchem.a130202
   PubMed Web of Science ®Google Scholar
• Tarentino, A. L., & Plummer, T. H. (1993). The first demonstration of a procaryotic glycosylasparaginase. Biochemical and Biophysical Research Communications, 197(1), 179–186. https://doi.org/10.1006/bbrc.1993.2457
   PubMed Web of Science ®Google Scholar
• Tikkanen, R., Enomaa, N., Riikonen, A., Ikonen, E., & Peltonen, L. (1995). Intracellular sorting of aspartylglucosaminidase: The role of N-linked oligosaccharides and evidence of Man-6-P-independent lysosomal targeting. DNA and Cell Biology, 14(4), 305–312. https://doi.org/10.1089/dna.1995.14.305
   PubMed Web of Science ®Google Scholar
• Tikkanen, R., Peltola, M., Oinonen, C., Rouvinen, J., & Peltonen, L. (1997). Several cooperating binding sites mediate the interaction of a lysosomal enzyme with phosphotransferase. The EMBO Journal, 16(22), 6684–6693. https://doi.org/10.1093/emboj/16.22.6684
   PubMed Web of Science ®Google Scholar
• Tikkanen, R., Riikonen, A., Oinonen, C., Rouvinen, R., & Peltonen, L. (1996). Functional analyses of active site residues of human lysosomal aspartylglucosaminidase: Implications for catalytic mechanism and autocatalytic activation. The EMBO Journal, 15(12), 2954–2960. https://doi.org/10.1002/j.1460-2075.1996.tb00658.x
   PubMed Web of Science ®Google Scholar
• Valente, R. P. da P., Souza, R. C. de, de Medeiros Muniz, G., Ferreira, J. E. V., de Miranda, R. M., E Lima, A. H. L., & Vianez Junior, J. L. da S. G. (2020). Using Accelerated Molecular Dynamics Simulation to elucidate the effects of the T198F mutation on the molecular flexibility of the West Nile virus envelope protein. Scientific Reports, 10(1), 9625. https://doi.org/10.1038/s41598-020-66344-8
   Google Scholar